Taiwan guideline on oral pre-exposure prophylaxis for HIV prevention – 2018 update
| Autor: | Kuan Sheng Wu, Stephane Wen-Wei Ku, Nai Ying Ko, Chia Wen Li, Isaac Yen Hao Chu, Huei Jiuan Wu, Shu Sheng Chen, Han Siong Toh, Chia-Jui Yang, Hsi Hsun Lin, Jiann Horng Kuo |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Microbiology (medical) medicine.medical_specialty Anti-HIV Agents 030106 microbiology lcsh:QR1-502 Taiwan MEDLINE HIV Infections lcsh:Microbiology Medication Adherence Men who have sex with men law.invention Sexual and Gender Minorities 03 medical and health sciences Pre-exposure prophylaxis 0302 clinical medicine Acquired immunodeficiency syndrome (AIDS) Randomized controlled trial law medicine Humans Immunology and Allergy 030212 general & internal medicine Randomized Controlled Trials as Topic Acquired Immunodeficiency Syndrome General Immunology and Microbiology business.industry General Medicine Guideline medicine.disease Infectious Diseases Systematic review Family medicine Practice Guidelines as Topic Serodiscordant Pre-Exposure Prophylaxis business Systematic Reviews as Topic |
| Zdroj: | Journal of Microbiology, Immunology and Infection, Vol 53, Iss 1, Pp 1-10 (2020) |
| ISSN: | 1684-1182 |
| DOI: | 10.1016/j.jmii.2019.09.003 |
| Popis: | Pre-exposure prophylaxis (PrEP) for prevention of human immunodeficiency virus infection is proved to be effective and has been implemented worldwide. This article introduces the guideline development and revised recommendations and guidance on PrEP provision in the updated Taiwan PrEP guideline. The Taiwan PrEP guideline writing group searched randomized controlled trials and guidelines published before October 2017 through Medline/PubMed, Cochrane Database, Embase and ClinicalTrials.gov database. Keywords included pre(-)exposure prophylaxis, PrEP, Truvada, tenofovir, HIV, and AIDS. Each selected article was assessed by two authors using the Grading of Recommendations Assessment, Development and Evaluation. External reviewers were invited to independently evaluate the revised manuscript per the Appraisal of Guidelines for Research and Evaluation II. Before publication, a public consultation was held to reach consensus on the updated guideline among providers, civil society, and Taiwan Centers for Disease Control. Four systematic reviews and 28 original articles were reviewed by Taiwan PrEP writing group. The second version of the Taiwan PrEP guideline was released in March 2018. We recommended daily PrEP use for the following populations: strong recommendation and high quality of evidence for men who have sex with men (MSM) and transgender women (TGW), as well as heterosexual serodiscordant couples; weak recommendation and high quality of evidence for people who inject drugs, while weak recommendation and moderate quality of evidence for at-risk heterosexual men and women. There is high-quality evidence for event-driven PrEP in MSM and likely TGW, and we additionally recognized these key populations could benefit from such dosing regimen. Keywords: Human immunodeficiency virus, Pre-exposure prophylaxis, PrEP, Taiwan |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|